Vera Bradley Foundation for Breast Cancer Names Stephanie Scheele Executive Director
July 19 2022 - 9:20AM
The Vera Bradley Foundation for Breast Cancer (the "Foundation")
today announced, after a national search, it has named Stephanie
Scheele as its new Executive Director.
Scheele has held the post of Chief Purpose and Communication
Officer of Vera Bradley, Inc. (the “Company”) since October 2021,
responsible for the Company’s enterprise-wide environmental, social
and governance (ESG) efforts, including oversight of the Vera
Bradley Foundation for Breast Cancer. Scheele joined the Company in
2001 and was the driving force behind various marketing and
creative initiatives during her tenure, advancing the Vera Bradley
brand’s marketing to an integrated, customer-segmented,
research-based approach. She was named VP, Marketing Strategy and
Operations in 2015; promoted to Interim Chief Marketing Officer in
2017; and promoted to Chief Marketing Officer in 2018. Prior to
joining Vera Bradley, Inc., Scheele worked for Sunrise Greetings, a
subsidiary of Hallmark. Scheele has served on the Foundation Board
of Directors since 2018.
“We are absolutely thrilled to name Stephanie Scheele Executive
Director of the Foundation. Stephanie has served on our board and
has worked tirelessly over the last several years on fundraising
efforts for the Foundation,” shared Ruth Cook, Chair of the Vera
Bradley Foundation Board. “Her strategic, marketing, and creative
expertise coupled with her institutional knowledge of the
Foundation will be instrumental as we elevate funding for
life-saving research that is impacting women, men, and their loved
ones worldwide.”
Since 2000, the Foundation has provided $37.5 million of funding
to the Indiana University School of Medicine (“IU School of
Medicine”), allowing them to amass the talent, technology, and
resources to become a national leader in targeted breast cancer
therapies, specifically for triple negative breast cancer. In April
2022, the Foundation made an additional gift commitment of $12.5
million to IU School of Medicine, bringing the non-profit’s total
commitment to breast cancer research to $50 million. The
Foundation’s ongoing support led to the 2018 creation of the Vera
Bradley Foundation Center for Breast Cancer Research at the Indiana
University Melvin and Bren Simon Comprehensive Cancer Center (the
“IU Cancer Center”) where more than 30 investigators collaborate on
breast cancer discoveries. In 2019, the IU Cancer Center was
designated a Comprehensive Cancer Center, the highest level of
recognition awarded by the National Cancer Institute for research
excellence.
Scheele noted, “I am honored and excited to accept the position
of Executive Director of the Foundation. I am intensely passionate
about our cause and see a future where a diagnosis of breast cancer
is not scary or overwhelming. The Foundation has and will continue
to provide hope to countless women and men, along with their
families. I am extremely grateful for each of the dedicated servant
leaders at the IU Cancer Center working tirelessly to perfect
therapies and for all of the donors and volunteers that make this
work possible.”
ABOUT VERA BRADLEY FOUNDATION FOR BREAST
CANCER
The Vera Bradley Foundation for Breast Cancer raises funds for
breast cancer research to find a cure and to improve the lives of
the many affected by this disease. The Foundation has contributed
$37.5 million to the Vera Bradley Foundation Center for Breast
Cancer Research at the Indiana University School of Medicine and
has pledged to raise an additional $12.5 million. The Center is
focused on developing and dramatically improving therapies for some
of the most difficult-to-treat types of breast cancer. Funds are
raised through special events, partner events, and individual
donations. For more information, visit www.verabradley.org.
Press ContactGreg JaegerDirector of Public
Relations & Social Media, Vera
Bradleygjaeger@verabradley.com
Vera Bradley (NASDAQ:VRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vera Bradley (NASDAQ:VRA)
Historical Stock Chart
From Sep 2023 to Sep 2024